Oncology

Your Unread Messages

See All

Your Article Summary

See Latest Articles

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
Blood, 11/04/09

Byrd JC et al. – The addition of lumiliximab to FCR therapy is feasible, achieves a high CR rate, and does not appear to enhance toxicity in previously treated patients with CLL.

• A phase 1/2 dose escalation study of lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients
• 31patients received either 375 mg/m2 (n = 3) or 500 mg/m2 (n = 28) of lumiliximab in combination with FCR for 6 cycles

• ORR was 65% with 52% of patients achieving a CR
• Median PFS for all responders was 28.7 months

Today in Leukemia/Lymphoma...keeping you current

Receive free subspecialty "5-minute updates" via email

A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy
Blood, 11/24/09

In vivo biotinylation of the vasculature in B cell lymphoma identifies BST-2 as a target for antibody-based therapy
Blood, 11/24/09

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 acute myeloid leukemias
Blood, 11/24/09

 See all of Leukemia/Lymphoma

Today in Pharmacology/Therapy...keeping you current

Receive free subspecialty "5-minute updates" via email

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
Breast Cancer Research and Treatment, 11/24/09

Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab
British Journal of Haematology, 11/24/09

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
Annals of Hematology, 11/24/09

 See all of Pharmacology/Therapy